Current Colorectal Cancer Reports

, Volume 11, Issue 3, pp 112–117 | Cite as

Hereditary Non-polyposis Colorectal Cancer: Prevention and Therapeutic Options

  • M. Dhooge
  • R. Coriat
  • S. Grandjouan
  • C. Brezault
  • J. Dréanic
  • S. Chaussade
Prevention and Early Detection (R Benamouzig, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Prevention and Early Detection


Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common hereditary colorectal cancer (CRC) syndrome. The first and foremost preventive measure is to identify patients with LS among CRC patients. This requires the screening of colorectal cancer through polymerase chain reaction-based microsatellite instability (MSI) testing or immunohistochemistry to look for a loss of expression of one of the mismatch repair (MMR) proteins and the referral of selected patients to genetic counseling. In LS patients, annual or biannual complete colonoscopy with chromoendoscopy is the only validated way to significantly reduce mortality related to CRC with the greatest quality-adjusted life expectancy benefit compared with prophylactic surgery. In the case of diagnosis of colonic cancer, a subtotal colectomy with an ileo-rectal anastomosis is recommended, in order to decrease the risk of metachronous CRC. However, segmental surgery can be discussed on an individual basis. Chemoprevention with aspirin seems to be efficient in decreasing colorectal cancer risk in LS, but the minimum effective dose and potential adverse events associated with long-term use are not yet known. The option of taking low-dose aspirin might be discussed with mutated gene carriers regarding the benefit and risks of the treatment.


Lynch syndrome HNPCC MMR genes Molecular screening Colorectal cancer Guidelines Endoscopic screening Chromoendoscopy Subtotal colectomy Aspirin Chemoprevention 


Compliance with Ethics Guidelines

Conflict of Interest

Marion Dhooge, Romain Coriat, Sophie Grandjouan, Catherine Brezault, Johann Dreanic, and Stanislas Chaussade declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Douglas JA, Gruber SB, Meister KA, Bonner J, Watson P, Krush AJ, et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA. 2005;294(17):2195–202.CrossRefPubMedGoogle Scholar
  2. 2.
    Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med. 1966;117(2):206–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Radman M, Wagner R. Carcinogenesis. Missing mismatch repair. Nature. 1993;366(6457):722.CrossRefPubMedGoogle Scholar
  5. 5.•
    Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23. European recommendations for clinical management of Lynch syndrome.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Umar A, Boland CR, Terdiman JP, Syngal S, De la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37(9):641–5.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 1993;75(6):1227–36.CrossRefPubMedGoogle Scholar
  10. 10.
    De la Chapelle A, Peltomäki P. Genetics of hereditary colon cancer. Annu Rev Genet. 1995;29:329–48.CrossRefPubMedGoogle Scholar
  11. 11.
    Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481–7.CrossRefPubMedGoogle Scholar
  12. 12.••
    Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A, Brea A, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61(6):865–72. The authors show that routine molecular screening has better sensitivity for detecting mutation carriers than the Bethesda guidelines.CrossRefPubMedGoogle Scholar
  13. 13.
    Tranø G, Sjursen W, Wasmuth HH, Hofsli E, Vatten LJ. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br J Cancer. 2010;102(3):482–8.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93–104.CrossRefPubMedGoogle Scholar
  15. 15.
    Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69–79.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.•
    Kastrinos F, Syngal S. Screening patients with colorectal cancer for lynch syndrome: what are we waiting for? JCO. 2012;30(10):1024–7. The authors show how crucial it is to adopt systematic approaches to evaluate patients with CRC for Lynch syndrome.CrossRefGoogle Scholar
  17. 17.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.Google Scholar
  18. 18.
    Mange S, Bellcross C, Cragun D, Duquette D, Gorman L, Hampel H, et al. Creation of a network to promote universal screening for Lynch syndrome: the Lynch Syndrome Screening Network. J Genet Couns. 2014.Google Scholar
  19. 19.
    Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut. 2002;50(3):382–6.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Lynch HT, Smyrk T, Jass JR. Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Semin Surg Oncol. 1995;11(6):406–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Lynch HT, De la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919–32.CrossRefPubMedGoogle Scholar
  22. 22.
    De Jong AE, Hendriks YMC, Kleibeuker JH, De Boer SY, Cats A, Griffioen G, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130(3):665–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108(5):1405–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Haanstra JF, Kleibeuker JH, Koornstra JJ. Role of new endoscopic techniques in Lynch syndrome. Fam Cancer. 2013;12(2):267–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Brown SR, Baraza W, Hurlstone P. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. Cochrane Database Syst Rev. 2007;4:CD006439.PubMedGoogle Scholar
  26. 26.
    Hurlstone DP, Karajeh M, Cross SS, McAlindon ME, Brown S, Hunter MD, et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective « back-to-back » endoscopic study. Am J Gastroenterol. 2005;100(10):2167–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Hüneburg R, Lammert F, Rabe C, Rahner N, Kahl P, Büttner R, et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy. 2009;41(4):316–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Lecomte T, Cellier C, Meatchi T, Barbier JP, Cugnenc PH, Jian R, et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol. 2005;3(9):897–902.CrossRefPubMedGoogle Scholar
  29. 29.
    Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet. 1995;345(8958):1183–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Stoffel EM, Turgeon DK, Stockwell DH, Zhao L, Normolle DP, Tuck MK, et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila). 2008;1(6):470–5.CrossRefGoogle Scholar
  31. 31.
    Vasen HFA, Abdirahman M, Brohet R, Langers AMJ, Kleibeuker JH, Van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138(7):2300–6.CrossRefPubMedGoogle Scholar
  32. 32.•
    Provenzale D, Jasperson K. NCCN clinical practice guidelines in oncology for genetic/familial high-risk assessment: colorectal cancer. National Comprehensive Cancer Network; 2014. US recommendations for clinical management of familial high risk of Colorectal Cancer including Lynch Syndrome.Google Scholar
  33. 33.••
    Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10. The authors show that MSH6 mutations are associated with markedly lower cancer risks than MLH1 or MSH2 mutations.CrossRefPubMedGoogle Scholar
  34. 34.••
    Ten Broeke SW, Brohet RM, Tops CM, Van der Klift HM, Velthuizen ME, Bernstein I, et al. Lynch syndrome caused by Germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2014. The authors reported markedly lower risks of colorectal cancer and endometrial cancer in PMS2 mutations carriers than those previously reported for the other MMR mutations.Google Scholar
  35. 35.
    Barrow E et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Buecher B, Kirzin S, Karoui M, Ansquer Y, Parc Y. Chirurgie prophylactique des cancers avec prédisposition génétique. Syndrome HNPCC/Lynch. Institut National du Cancer; 2009 p. 47.Google Scholar
  37. 37.
    Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129(10):787–96.CrossRefPubMedGoogle Scholar
  38. 38.
    tot Nederveen Cappel WH DV, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum. 2002;45(12):1588–94.CrossRefGoogle Scholar
  39. 39.
    Rodríguez-Bigas MA, Vasen HF, Pekka-Mecklin J, Myrhøj T, Rozen P, Bertario L, et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg. 1997;225(2):202–7.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    tot Nederveen Cappel WH DV, Buskens E, Van Duijvendijk P, Cats A, Menko FH, Griffioen G, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut. 2003;52(12):1752–5.CrossRefGoogle Scholar
  41. 41.
    Olschwang S, Laurent-Puig P, Eisinger F, Millat B. An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. Gut. 2005;54(1):169.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal colectomy versus on-table irrigation and anastomosis. Br J Surg. 1995;82(12):1622–1627.Google Scholar
  43. 43.
    Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.CrossRefPubMedGoogle Scholar
  44. 44.
    Burn J, Bishop DT, Mecklin J-P, Macrae F, Möslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567–78.CrossRefPubMedGoogle Scholar
  45. 45.•
    Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. The authors show a decrease in colorectal cancer risk by using aspirin in HNPCC patients.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. Fam Cancer. 2013;12(4):707–18.CrossRefPubMedGoogle Scholar
  47. 47.
    Rijcken FEM, Hollema H, Van der Zee AGJ, Van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Sulindac treatment in hereditary non-polyposis colorectal cancer. Eur J Cancer. 2007;43(8):1251–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V, Roselli M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res. 2007;27(5A):3147–62.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • M. Dhooge
    • 1
    • 3
  • R. Coriat
    • 1
    • 2
    • 3
  • S. Grandjouan
    • 1
    • 3
  • C. Brezault
    • 1
  • J. Dréanic
    • 1
  • S. Chaussade
    • 1
    • 2
  1. 1.Department of GastroenterologyCochin Teaching HospitalParisFrance
  2. 2.Faculté de médecineUniversité Paris DescartesParisFrance
  3. 3.Department of Clinical OncogeneticCochin Teaching HospitalParisFrance

Personalised recommendations